对奥克林等人的回复。关于“霍普金斯等人。肺免疫预后指数在非小细胞肺癌患者一线阿替唑单抗联合治疗中的价值：IMPOWER150试验的亚组分析。2021年，，1176”的评论

1

Cancers (Basel). 2021 Jul 27;13(15):3763. doi: 10.3390/cancers13153763.

2

Cancers (Basel). 2021 Jul 20;13(14):3624. doi: 10.3390/cancers13143624.

3

Cancers (Basel). 2021 Mar 9;13(5):1176. doi: 10.3390/cancers13051176.

4

Cancer. 2019 Oct 15;125(20):3526-3534. doi: 10.1002/cncr.32368. Epub 2019 Jul 9.

5

Expert Rev Respir Med. 2020 Feb;14(2):125-136. doi: 10.1080/17476348.2020.1701439. Epub 2019 Dec 12.

6

Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.

7

Cancers (Basel). 2021 May 7;13(9):2238. doi: 10.3390/cancers13092238.

8

Adv Ther. 2020 May;37(5):2116-2126. doi: 10.1007/s12325-020-01292-3. Epub 2020 Mar 19.

9

Cancer Biomark. 2018;22(3):467-476. doi: 10.3233/CBM-171089.

10

JAMA Oncol. 2020 Apr 1;6(4):512-518. doi: 10.1001/jamaoncol.2019.5241.

Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176".